{"disease":{"id":"relapsing-forms-of-multiple-sclerosis","name":"Relapsing forms of multiple sclerosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"diroximel-fumarate","indication_name":"Relapsing Forms of Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vumerity","generic_name":"DIROXIMEL FUMARATE","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":71,"revenue":"500","mechanism":"Vumerity works by binding to the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation in the central nervous system."},{"drug_id":"diroximel-fumarate","indication_name":"Relapsing forms of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vumerity","generic_name":"DIROXIMEL FUMARATE","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":71,"revenue":"500","mechanism":"Vumerity works by binding to the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation in the central nervous system."},{"drug_id":"fingolimod-hydrochloride","indication_name":"Relapsing Forms of Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FINGOLIMOD HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"ublituximab-xiiy","indication_name":"Relapsing forms of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BRIUMVI","generic_name":"UBLITUXIMAB-XIIY","company_name":"TG THERAPEUTICS, INC","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"vumerity","indication_name":"Relapsing forms of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vumerity","company_name":"University of Nebraska","drug_phase":"marketed","molecular_target":"Nuclear factor erythroid 2-related factor 2, Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"fty720","indication_name":"Treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FTY720","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)","drug_class":"Sphingosine-1-phosphate receptor modulator; Immunomodulator","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01201356","title":"Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4125,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02230969","title":"Plegridy Observational Program","phase":"","overall_status":"COMPLETED","enrollment_count":1208,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT06251986","title":"A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":310,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07483632","title":"A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":185,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT05083923","title":"A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT05798520","title":"A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT02097849","title":"Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT06681623","title":"A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Neurology Center of New England P.C.","has_results":false},{"nct_id":"NCT04676555","title":"Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}